Shares of COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) have received a consensus rating of "Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $33.60.
Several analysts have recently weighed in on CMPS shares. Maxim Group decreased their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. HC Wainwright reduced their target price on shares of COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th.
Read Our Latest Report on COMPASS Pathways
NASDAQ:CMPS traded down $0.22 during mid-day trading on Friday, hitting $4.41. 848,229 shares of the company's stock traded hands, compared to its average volume of 1,372,321. The firm has a 50 day moving average of $4.10 and a two-hundred day moving average of $5.57. COMPASS Pathways has a 12 month low of $3.16 and a 12 month high of $12.75. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $301.73 million, a price-to-earnings ratio of -2.00 and a beta of 2.28.
Several institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of COMPASS Pathways during the 4th quarter worth approximately $41,000. Wealthfront Advisers LLC acquired a new stake in shares of COMPASS Pathways in the 4th quarter valued at $43,000. Flagship Harbor Advisors LLC bought a new position in shares of COMPASS Pathways in the 4th quarter valued at $43,000. Conservest Capital Advisors Inc. raised its holdings in shares of COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after buying an additional 3,000 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of COMPASS Pathways during the 3rd quarter worth $131,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.